Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer

Melissa L. Johnson*, Jyoti D. Patel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related death in the United States. Survival for patients with advanced disease remains meager with standard platinum-based doublet therapy even given initially. Improved efficacy and tolerability of third-generation chemotherapies and small-molecule inhibitors has prompted the evaluation of these agents in the maintenance setting in order to enhance current outcomes. Two separate strategies have evolved: the introduction of a non-cross-resistant drug immediately following first-line or induction chemotherapy (switch maintenance), or the continuation of the non-platinum partner initially introduced during induction (continuation maintenance). Here we review the available clinical trial data evaluating both maintenance strategies, and offer our assessment of their contemporary clinical implications and cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalSeminars in Oncology
Volume41
Issue number1
DOIs
StatePublished - Feb 2014

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this